Literature DB >> 30810053

The emergence of Ephexin5 as a therapeutic target in Alzheimer's disease.

Emily K Cook1, Gabrielle L Sell2, Thomas B Schaffer3, Seth S Margolis1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30810053      PMCID： PMC6715421          DOI： 10.1080/14728222.2019.1586884

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


× No keyword cloud information.
  19 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses.

Authors:  Eric M Blalock; James W Geddes; Kuey Chu Chen; Nada M Porter; William R Markesbery; Philip W Landfield
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

Review 3.  Clinical practice. Early Alzheimer's disease.

Authors:  Claudia H Kawas
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

Review 4.  The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.

Authors:  Sam Gandy
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

6.  Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand.

Authors:  Y Morishima; Y Gotoh; J Zieg; T Barrett; H Takano; R Flavell; R J Davis; Y Shirasaki; M E Greenberg
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

7.  Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease.

Authors:  E Masliah; M Mallory; M Alford; R DeTeresa; L A Hansen; D W McKeel; J C Morris
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

Review 8.  Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease.

Authors:  John B Standridge
Journal:  Curr Alzheimer Res       Date:  2006-04       Impact factor: 3.498

9.  EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation.

Authors:  Seth S Margolis; John Salogiannis; David M Lipton; Caleigh Mandel-Brehm; Zachary P Wills; Alan R Mardinly; Linda Hu; Paul L Greer; Jay B Bikoff; Hsin-Yi Henry Ho; Michael J Soskis; Mustafa Sahin; Michael E Greenberg
Journal:  Cell       Date:  2010-10-29       Impact factor: 41.582

Review 10.  Synaptic slaughter in Alzheimer's disease.

Authors:  Paul D Coleman; Pamela J Yao
Journal:  Neurobiol Aging       Date:  2003-12       Impact factor: 4.673
View more
  1 in total

1.  Deleting a UBE3A substrate rescues impaired hippocampal physiology and learning in Angelman syndrome mice.

Authors:  Gabrielle L Sell; Wendy Xin; Emily K Cook; Mark A Zbinden; Thomas B Schaffer; Robert N O'Meally; Robert N Cole; Seth S Margolis
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.